A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.

BMC Cancer · 2024 · PMC10840225 · PMID 38317094

Europe PMC DOI

hedged sentence

0.0820

closest p · 1.6× alpha

0.0820

boldest claim

The sentences

did not reach statistical significancep = 0.082so close (0.05 < p ≤ 0.1)

Among the common mutation group, the ORR for the Del 19 group was numerically higher than that for the L858R group; however, it is important to note that this difference did not reach statistical significance (82.6% vs. 73.3%, p = 0.082).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.